California State Teachers Retirement System lifted its position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 9,187.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 80,962,062 shares of the medical research company’s stock after acquiring an additional 80,090,362 shares during the quarter. California State Teachers Retirement System owned approximately 0.14% of Edwards Lifesciences worth $7,323,828,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Hanson & Doremus Investment Management acquired a new stake in Edwards Lifesciences during the 1st quarter valued at $25,000. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the third quarter worth $25,000. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $26,000. RMG Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the first quarter valued at $26,000. Finally, Pin Oak Investment Advisors Inc. acquired a new position in Edwards Lifesciences during the second quarter valued at $26,000. Institutional investors and hedge funds own 79.46% of the company’s stock.
Analyst Ratings Changes
Several research firms have weighed in on EW. Truist Financial lifted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $87.00 to $101.00 in a report on Friday, July 24th. BTIG Research boosted their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Royal Bank Of Canada upped their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Finally, Citigroup boosted their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $100.27.
Edwards Lifesciences Stock Performance
Shares of EW opened at $86.73 on Wednesday. The company has a market capitalization of $49.94 billion, a PE ratio of 49.85, a price-to-earnings-growth ratio of 2.36 and a beta of 0.85. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The company’s fifty day moving average price is $89.63 and its 200 day moving average price is $85.70.
Edwards Lifesciences (NYSE:EW – Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.
Insider Buying and Selling
In related news, VP Annette Brüls sold 2,644 shares of the company’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares in the company, valued at $1,618,200.32. This represents a 12.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares of the company’s stock, valued at approximately $1,353,880.08. The trade was a 3.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 5,045 shares of company stock valued at $457,749. 0.31% of the stock is owned by company insiders.
Edwards Lifesciences Profile
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
See Also
- Five stocks we like better than Edwards Lifesciences
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
